Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

The contrasting properties of 2 xenogenic erythrocyte-reactive natural antibodies in commercial ducks.

Posted by on in 2012
  • Font size: Larger Smaller
  • Hits: 1590
  • Print
Cotter PF. 2012. Poult Sci. 91(3):653-9.

Cotter Laboratory, Arlington, MA 02476, USA.


Sera obtained from commercial drakes on days 14 and 38 of age were tested by microtiter for the capacity to agglutinate and lyse rabbit (Rb) and human (HuO) erythrocytes. Three agglutination types, differing by strength, were recognized: HA1 (strong), HA2 (weak), and HA45 (very weak).Two degrees of lysis: L(100) (complete) and L(50) (partial), measured complement activity. Day 14 sera agglutinated Rb (average log(2) titers: HA1 = 1.5, HA2 = 4.1) and lysed Rb (average log(2) titers: L(100) = 2, L(50) = 2.5) but only 8/115 (~9%) agglutinated HuO (HA45 = 0.4) while most (>80%) lysed HuO (average log(2) titers: L(100) = 1.3, L(50) = 1.8). Both Rb and HuO agglutination and lysis titers were higher by d 38. At that age, all ducks lysed HuO and 50% of ducks acquired a capacity to agglutinate these cells with more strength. However, the quality of HuO agglutination could not be differentiated into HA1 or HA2 types. Average d 38 log(2) titers of all measures were Rb: HA1 = 4, HA2 = 8.4, L(100) = 3, and L(50) = 4; and HuO: HA = 2.8, L(100) = 3.9, and L(50) = 1.2. The quality of the Rb agglutination suggested the participation of both IgM and standard-sized IgY antibodies. Lysis of Rb may occur by both classic and alternate complement pathways. The HuO lysis appears to depend primarily on the alternate complement pathway. It is suggested that multiple measurement systems such as these offer a practical way of obtaining information on immunity in experiments where the chief interest lies elsewhere.

[PubMed - indexed for MEDLINE]
Last modified on